Spoulou Vana I, Tsoumas Dimitris L, Papaevangelou Vana G, Mostrou Glykeria I, Theodoridou Maria C
1st Department of Pediatrics, Division of Infectious Diseases, Aghia Sophia Children's Hospital, Athens University School of Medicine, Thivon and M. Asias St., Goudi 11527, Athens, Greece.
Vaccine. 2005 Nov 16;23(46-47):5289-93. doi: 10.1016/j.vaccine.2005.06.002. Epub 2005 Jun 21.
A 7-valent CRM197 conjugate pneumococcal vaccine (PCV)-induced immune response were evaluated in all Greek symptomatic HIV-1 infected children and 21 age-matched controls. PCV immunogenicity was inferior in HIV patients compared with the controls although differences in geometric mean concentrations (GMC) were not significant (P>.05). Immune responses were strikingly different after anamnestic immunization, given in all study subjects, 12 months later. HIV-positive children achieved lower GMC for all serotypes compared with the controls (P=.002) and avidity for all except serotype 6B was inferior compared to baseline. Long-term PCV effectiveness is expected to be reduced among symptomatic HIV-1 infected children.
在所有有症状的希腊HIV-1感染儿童和21名年龄匹配的对照中评估了7价CRM197结合肺炎球菌疫苗(PCV)诱导的免疫反应。尽管几何平均浓度(GMC)差异不显著(P>0.05),但与对照组相比,HIV患者中PCV的免疫原性较差。在12个月后对所有研究对象进行回忆免疫后,免疫反应有显著差异。与对照组相比,HIV阳性儿童所有血清型的GMC较低(P=0.002),除6B血清型外,所有血清型的亲和力均低于基线。预计在有症状的HIV-1感染儿童中,PCV的长期有效性会降低。